Keynote Presentation: Kevin Bailey

Optimizing the Speed and Throughput of Therapeutic Antibody Development
Sunday, February 24, 2013, 4:45pm-5:45pm PST

Optimizing the Speed and Throughput of Therapeutic Antibody Development


Advances in target discovery and validation coupled with the ability to generate fully human antibodies against these targets is increasing the rate with which biotechnology companies can move promising new therapeutics into clinical development.  To meet this challenge, new rapid development paradigms are needed to identify the best candidates and deliver quality therapeutics to patients.  Regeneron's speed to clinic development strategy along with our approach for late-stage therapeutic development will be discussed in conjunction with an overview of the technologies used to facilitate these efforts.
 

Kevin Bailey

Kevin Bailey has 25 years of experience in the biopharmaceutical industry, 20 of those at Regeneron Pharmaceuticals, Inc., where he is Vice President of Preclinical Manufacturing and Process Development.  He is responsible for leading all development efforts for clinical and commercial-scale manufacturing processes for all antibodies and other products in Regeneron Pharmaceuticals expanding development pipeline.  He received his Ph.D. in biochemical engineering from Rutgers University in 1987.